Intermittent chemotherapy for metastatic hormone refractory prostate cancer
Authors:
- Amy M. LinALAmy M. Lin
- Charles J. RyanCRCharles J. Ryan
- Eric J. SmallESEric J. Small
- 1 March 2007
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 61 (3) , 243-254
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Quality of Life and Pain in Advanced Stage Prostate Cancer: Results of a Southwest Oncology Group Randomized Trial Comparing Docetaxel and Estramustine to Mitoxantrone and PrednisoneJournal of Clinical Oncology, 2006
- Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate CancerNew England Journal of Medicine, 2004
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate CancerNew England Journal of Medicine, 2004
- Cancer Statistics, 2001CA: A Cancer Journal for Clinicians, 2001
- Epirubicin-Based Chemotherapy in Metastatic Breast Cancer Patients: Role of Dose-Intensity and Duration of TreatmentJournal of Clinical Oncology, 2000
- Interrupted versus Continuous Chemotherapy in Patients with Metastatic Breast CancerNew England Journal of Medicine, 1991
- Intermittent versus Continuous Chemotherapy for Breast CancerNew England Journal of Medicine, 1988
- Improving the Quality of Life during Chemotherapy for Advanced Breast CancerNew England Journal of Medicine, 1987
- A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer A Cancer and Leukemia Group B studyAmerican Journal of Clinical Oncology, 1984
- HypothesisAmerican Journal of Clinical Oncology, 1983